Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Genzyme Corp, Medical Devices Deals, 2011 to YTD 2017 11
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Genzyme Corp, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Genzyme Acquires Caprelsa from AstraZeneca 15
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 16
Venture Financing 17
Edimer Pharma Raises US$18 Million In Series B Financing 17
Ultragenyx Pharma Raises US$75 Million In Series B Financing 19
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 21
Fate Therapeutics Secures Venture Financing 23
Fate Therapeutics Raises US$36 Million In Series B Financing 25
Partnerships 27
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 27
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 28
Recursion Pharma Enters into Research Agreement with Genzyme 29
Ablynx Enters into Research Agreement with Genzyme 30
Cystic Fibrosis Foundation Therapeutics Expands Research Agreement with Genzyme 31
Voyager Therapeutics Enters into Development Agreement with Genzyme 32
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 33
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 34
Genzyme Enters Into Research Agreement With Cleveland Clinic 35
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 36
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 38
Genzyme Enters Into Research Agreement With Cystic Fibrosis Foundation Therapeutics 39
ChemRar Enters Into Co-Development Agreement With Genzyme 40
Merger 41
Sanofi Japan and Genzyme Japan Merge 41
Licensing Agreements 42
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 42
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 43
Equity Offering 44
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 44
KaloBios Pharma Completes IPO For US$70 Million 46
Asset Transactions 48
Admedus Acquires Manufacturing Facility From Genzyme Australasia 48
Genzyme Completes Sale Of Pharma Intermediates Business To International Chemical Investors 49
Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme 50
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 51
Acquisition 53
Sanofi-Aventis Completes Acquisition Of Genzyme 53
Genzyme Corp – Key Competitors 56
Genzyme Corp – Key Employees 57
Genzyme Corp – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Joint Venture 61
Recent Developments 62
Government and Public Interest 62
Dec 20, 2016: Sanofi Genzyme Announces Recipients of 2016 Patient Advocacy Leadership (PAL) Awards 62
Product News 64
11/10/2016: Genzyme Europe Receives CHMP Positive Opinion recommending change to the terms of the marketing authorisation for Caprelsa 64
10/06/2016: BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine (sargramostim) for Potential Public Health Emergency 65
03/03/2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease 66
Clinical Trials 68
Apr 11, 2017: Sanofi Genzyme to present data on GLD52 (GZ402668) at AAN 68
Feb 14, 2017: Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson’s Disease 69
Nov 17, 2016: Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease to Begin in the UK 70
Nov 04, 2016: Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease 71
Other Significant Developments 72
Mar 22, 2017: Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-to-Peer Education 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
Genzyme Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Genzyme Corp, Deals By Therapy Area, 2011 to YTD 2017 10
Genzyme Corp, Medical Devices Deals, 2011 to YTD 2017 11
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Genzyme Acquires Caprelsa from AstraZeneca 15
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 16
Edimer Pharma Raises US$18 Million In Series B Financing 17
Ultragenyx Pharma Raises US$75 Million In Series B Financing 19
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 21
Fate Therapeutics Secures Venture Financing 23
Fate Therapeutics Raises US$36 Million In Series B Financing 25
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 27
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 28
Recursion Pharma Enters into Research Agreement with Genzyme 29
Ablynx Enters into Research Agreement with Genzyme 30
Cystic Fibrosis Foundation Therapeutics Expands Research Agreement with Genzyme 31
Voyager Therapeutics Enters into Development Agreement with Genzyme 32
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 33
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 34
Genzyme Enters Into Research Agreement With Cleveland Clinic 35
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 36
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 38
Genzyme Enters Into Research Agreement With Cystic Fibrosis Foundation Therapeutics 39
ChemRar Enters Into Co-Development Agreement With Genzyme 40
Sanofi Japan and Genzyme Japan Merge 41
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 42
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 43
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 44
KaloBios Pharma Completes IPO For US$70 Million 46
Admedus Acquires Manufacturing Facility From Genzyme Australasia 48
Genzyme Completes Sale Of Pharma Intermediates Business To International Chemical Investors 49
Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme 50
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 51
Sanofi-Aventis Completes Acquisition Of Genzyme 53
Genzyme Corp, Key Competitors 56
Genzyme Corp, Key Employees 57
Genzyme Corp, Other Locations 58
Genzyme Corp, Subsidiaries 59
Genzyme Corp, Joint Venture 61